Zaiding Pharmaceutical Co., Ltd. and South Korea and the United States jointly develop EGFR targeted lung cancer drug hm61713

It is reported that hm61713 is the third generation irreversible tyrosine kinase inhibitor targeting EGFR mutation, targeting at T790M mutant tumors At the 2015 ASCO annual meeting, South Korea and the United States released the interim data of phase I / II clinical trials of hm61713, which showed that the drug performed well in terms of effectiveness and safety In July this year, South Korea and the United States reached an agreement with bringer Ingelheim, who obtained the R & D and global commercialization rights of hm61713 (bi1482694) except for South Korea, China and Hong Kong Du Ying, chairman and CEO of zaiding pharmaceutical, said zaiding is happy to cooperate with Han Meida Non small cell lung cancer (NSCLC) not only has a high demand for drugs in China, but also has a huge global population of patients The cooperation is committed to listing this potential target drug in China as soon as possible, and the company also hopes to cooperate more with Korea Meida China's non-small cell lung cancer patients account for 46% of the world's total patients, and this number will surge to 62% by 2020 This also shows that once hm61713 is listed in China, it will usher in a very broad market According to Dr Gwan sun Lee, CEO of Korea US pharmaceutical, zaiding Pharmaceutical Co., Ltd is a pharmaceutical company with perfect R & D system and capability, which will make it possible for hm61713 to be listed in China South Korea and the United States are eager to bring new treatment options for lung cancer patients in China as soon as possible About Korea US pharmaceutical, Korea US pharmaceutical is a multinational pharmaceutical enterprise with Korea as the main body, committed to the research and development of new drugs and commercialization At present, Korean American pharmaceutical has an industrial system integrating R & D, manufacturing and sales with Korea and China At present, South Korea and the United States have invested 20% of their sales in R & D at present, more than 20 projects are in the clinical trial stage, mainly covering the following three areas: 1) new long-term biological products based on lapcovery platform, including weekly insulin, weekly or monthly GLP-1 and combined drugs, mainly covering the fields of diabetes and obesity; 2) new tumor or autoimmune disease targeted drugs; 3) Fixed dose combination About zaiding pharmaceutical zaiding Pharmaceutical Co., Ltd is a Chinese pharmaceutical company dedicated to new drug research and development and commercialization At present, zaiding is building its strong commodity portfolio Zaiding has a world-class R & D team, and its main members have R & D experience in large multinational pharmaceutical companies or biotechnology companies At present, zaiding has successfully put five new candidate drugs into clinical trials Zaiding has also obtained the approval of the registration regulatory authority in the shortest time through the new registration channel, and has carried out a number of clinical trials of experimental new drugs in the United States.